3mla
From Proteopedia
(Difference between revisions)
m (Protected "3mla" [edit=sysop:move=sysop]) |
|||
(4 intermediate revisions not shown.) | |||
Line 1: | Line 1: | ||
- | {{STRUCTURE_3mla| PDB=3mla | SCENE= }} | ||
- | ===BaNadD in complex with inhibitor 1_02=== | ||
- | {{ABSTRACT_PUBMED_020578699}} | ||
- | == | + | ==BaNadD in complex with inhibitor 1_02== |
- | [[http://www.uniprot.org/uniprot/NADD_BACAC NADD_BACAC | + | <StructureSection load='3mla' size='340' side='right'caption='[[3mla]], [[Resolution|resolution]] 1.75Å' scene=''> |
+ | == Structural highlights == | ||
+ | <table><tr><td colspan='2'>[[3mla]] is a 2 chain structure with sequence from [https://en.wikipedia.org/wiki/Bacillus_anthracis Bacillus anthracis]. Full crystallographic information is available from [http://oca.weizmann.ac.il/oca-bin/ocashort?id=3MLA OCA]. For a <b>guided tour on the structure components</b> use [https://proteopedia.org/fgij/fg.htm?mol=3MLA FirstGlance]. <br> | ||
+ | </td></tr><tr id='method'><td class="sblockLbl"><b>[[Empirical_models|Method:]]</b></td><td class="sblockDat" id="methodDat">X-ray diffraction, [[Resolution|Resolution]] 1.75Å</td></tr> | ||
+ | <tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat" id="ligandDat"><scene name='pdbligand=DMS:DIMETHYL+SULFOXIDE'>DMS</scene>, <scene name='pdbligand=FMT:FORMIC+ACID'>FMT</scene>, <scene name='pdbligand=JJZ:4-[2-(ANTHRACEN-9-YLMETHYLIDENE)HYDRAZINO]-N-(3-CHLOROPHENYL)-4-OXOBUTANAMIDE'>JJZ</scene></td></tr> | ||
+ | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[https://proteopedia.org/fgij/fg.htm?mol=3mla FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=3mla OCA], [https://pdbe.org/3mla PDBe], [https://www.rcsb.org/pdb/explore.do?structureId=3mla RCSB], [https://www.ebi.ac.uk/pdbsum/3mla PDBsum], [https://prosat.h-its.org/prosat/prosatexe?pdbcode=3mla ProSAT]</span></td></tr> | ||
+ | </table> | ||
+ | == Function == | ||
+ | [https://www.uniprot.org/uniprot/NADD_BACAC NADD_BACAC] Catalyzes the reversible adenylation of nicotinate mononucleotide (NaMN) to nicotinic acid adenine dinucleotide (NaAD) (By similarity). | ||
+ | == Evolutionary Conservation == | ||
+ | [[Image:Consurf_key_small.gif|200px|right]] | ||
+ | Check<jmol> | ||
+ | <jmolCheckbox> | ||
+ | <scriptWhenChecked>; select protein; define ~consurf_to_do selected; consurf_initial_scene = true; script "/wiki/ConSurf/ml/3mla_consurf.spt"</scriptWhenChecked> | ||
+ | <scriptWhenUnchecked>script /wiki/extensions/Proteopedia/spt/initialview01.spt</scriptWhenUnchecked> | ||
+ | <text>to colour the structure by Evolutionary Conservation</text> | ||
+ | </jmolCheckbox> | ||
+ | </jmol>, as determined by [http://consurfdb.tau.ac.il/ ConSurfDB]. You may read the [[Conservation%2C_Evolutionary|explanation]] of the method and the full data available from [http://bental.tau.ac.il/new_ConSurfDB/main_output.php?pdb_ID=3mla ConSurf]. | ||
+ | <div style="clear:both"></div> | ||
+ | <div style="background-color:#fffaf0;"> | ||
+ | == Publication Abstract from PubMed == | ||
+ | Bacterial nicotinate mononucleotide adenylyltransferase encoded by the essential gene nadD plays a central role in the synthesis of the redox cofactor NAD(+). The NadD enzyme is conserved in the majority of bacterial species and has been recognized as a novel target for developing new and potentially broad-spectrum antibacterial therapeutics. Here we report the crystal structures of Bacillus anthracis NadD in complex with three NadD inhibitors, including two analogues synthesized in the present study. These structures revealed a common binding site shared by different classes of NadD inhibitors and explored the chemical environment surrounding this site. The structural data obtained here also showed that the subtle changes in ligand structure can lead to significant changes in the binding mode, information that will be useful for future structure-based optimization and design of high affinity inhibitors. | ||
- | + | Complexes of bacterial nicotinate mononucleotide adenylyltransferase with inhibitors: implication for structure-based drug design and improvement.,Huang N, Kolhatkar R, Eyobo Y, Sorci L, Rodionova I, Osterman AL, Mackerell AD, Zhang H J Med Chem. 2010 Jul 22;53(14):5229-39. PMID:20578699<ref>PMID:20578699</ref> | |
- | + | ||
- | + | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | |
- | < | + | </div> |
+ | <div class="pdbe-citations 3mla" style="background-color:#fffaf0;"></div> | ||
+ | == References == | ||
+ | <references/> | ||
+ | __TOC__ | ||
+ | </StructureSection> | ||
[[Category: Bacillus anthracis]] | [[Category: Bacillus anthracis]] | ||
- | [[Category: | + | [[Category: Large Structures]] |
- | [[Category: Eyobo | + | [[Category: Eyobo Y]] |
- | [[Category: Huang | + | [[Category: Huang N]] |
- | [[Category: Zhang | + | [[Category: Zhang H]] |
- | + | ||
- | + |
Current revision
BaNadD in complex with inhibitor 1_02
|